Trends in Mergers & Acquisitions
May 2006
Trends in Mergers & Acquisitions
The First Edition of PharmaVentures Business Review
Watch the whole program
Trends in Mergers & Acquisitions
PharmaVentures Business Review is a new cutting-edge television business show that provides viewers with effortless access to essential industry intelligence. As the first of its kind we expect this show to be watched by thousands throughout the pharma and biotech industry, as well as the financial sector.
PharmaVentures Business Review will keep you informed with our insightful coverage of major transactions and industry trends, as well as giving you exclusive access to topical interviews with senior executives and independent expert opinions.
To learn more about the major deals and transactions from the previous month’s industry activity, you should view PharmaDeals Intelligence bank, a comprehensive and global source of deals information. With financial information, news alerts and legal agreements, this searchable resource, which is compiled by analysts and consultants, is an essential deal making tool.
The Month in Review
Covers the following key deals:
- Bayer's acquisition of Schering AG
- Pfizer's acquisition of Rinat Neuroscience
- GlaxoSmithKline's deal with Sirna Therapeutics
- EPIX Pharmaceuticals' merger with Predix Pharmaceuticals
- Infinity Pharmaceuticals' merger with Discovery Partners International
The Business Report
A focus on some of the trends that PharmaVentures' business analysts have observed in the area of Mergers & Acquisitions between 2000 and 2005, using data extracted from PharmaVentures' proprietary deal information resource: PharmaDeals® Agreements.
Face-to-Face
This month's subject is the funding of the Australian biotech industry. To examine the important issues, we have conducted interviews with two key individuals:
- Alison Coutts
Director of Business Development, eGrowth Capital - Gavin Rezos Chief Executive Officer, pSivida
Meet the Experts
Dr Fintan Walton, CEO of PharmaVentures, leads a discussion with our expert panel on the topic of Mergers & Acquisitions within the biotech and pharmaceutical sector, debating key issues on current trends, key drivers for success and how to avoid the pitfalls.
On the panel this month:
- Charles Macfarlane
Executive Director Worldwide Alliances, Licensing and Acquisition, Procter & Gamble Company - Glyn Edwards
CEO, Antisoma; Deputy Chairman, UK Biotech Industry Association - Ulrich Kinzel
Corporate Finance, Nomura Code Securities
